Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia

Abstract

Eviprostat is a phytotherapeutic agent that has been used widely for more than 40 years in the treatment of benign prostatic hyperplasia (BPH) in Japan and Germany, and is known to have antioxidant activity. The present study investigated the effect of Eviprostat on the levels of the urinary oxidative stress marker 8-hydroxy-2'-deoxyguanosine (8-OHdG) in a rabbit model of surgical partial bladder outlet obstruction (PBOO) and in patients with lower urinary tract symptoms (LUTS) associated with BPH. In the rabbit model, 8-OHdG levels in urine collected after 3 weeks of PBOO were 3.8-fold higher than in the urine of sham-operated rabbits. When twice-daily Eviprostat was administered orally throughout the 3-week PBOO period, the increase in urinary 8-OHdG levels was suppressed by 70%. In the clinical study, nine patients who received Eviprostat for 4 weeks showed 2.5-fold lower urinary 8-OHdG levels than before treatment. During Eviprostat treatment, the total International Prostate Symptom Score (IPSS) decreased from 16.56 +/- 2.74 to 13.67 +/- 2.30 and the quality of life score from 4.22 +/- 0.40 to 3.22 +/- 0.46. The findings provide evidence that the antioxidant activity of Eviprostat is responsible for its beneficial effects in the treatment of BPH.

Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis‐induced chronic bladder ischemia

“…The present study, together with our previous report, 15 shows that Eviprostat reduces several kinds of pro‐inflammatory cytokines in the bladder tissue of AI and BOO rats 15 . Furthermore, Eviprostat has been shown to have a scavenging activity in vitro and in vivo 14,15,18 . These results strongly suggest that Eviprostat‐mediated inhibition of the increased bladder oxidative stress and inflammation caused by chronic bladder ischemia contribute to the protection of bladder function.…”

“…The day before removal of the bladder, urine was collected from the rats (6 in group 1, and 10 in groups 2 and 3) in a metabolic cage over a 24‐h period. 8‐OHdG was determined with an 8‐OHdG Check ELISA kit from Nikken Seil (Shizuoka, Japan), as described previously 15,18 . Eight weeks after surgery, rats were anesthetized with pentobarbital (25 mg/kg i.p.…”

Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying

“…The increase in MDA levels was partially suppressed by oral Eviprostat, consistent with a strong antioxidant action by Eviprostat in the bladder. The antioxidant action of Eviprostat has previously been demonstrated in the bladders of BOO rats5 and rats with atherosclerosis‐induced chronic bladder ischemia,12 in the prostate of rats with nonbacterial prostatitis,16–18 and in the urine of patients with BPH 19. Because we observed accumulation of leukocytes accompanied by an increase in MPO in the bladders of OE rats, we also investigated the effect of bladder OE on the levels of the proinflammatory cytokines IL‐1β, IL‐6, and CXCL1/CINC‐1 as indices of inflammation.…”

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

“…Other clinical studies carried out supported the use of phytotherapies from different plants such as Eviprostat (Matsumoto et al, 2010), Pygeum africanum extract (Chatelain et al, 1999), Stinging nettle root extract (Bazotonuno) (Schneider and Rübben, 2004), PR-2000 ( Tribulus terrestris ) (Sahu and Kumar, 2001), and others in the management of BPH but which are beyond the scope of this review as the actual polyphenols in these phytotherapies were not indicated in these studies.…”